Alembic Pharmaceuticals Ltd.

Alembic Pharmaceuticals Limited (NSE: APLLTD; BSE: 533573) is an Indian pharmaceutical company headquartered on Alembic Road, Vadodara, Gujarat. The business traces to 1907, when the Amin family's Alembic group was founded; Alembic Pharmaceuticals Ltd. itself was incorporated in 2010, when the pharma business was demerged from Alembic Limited (which remains a separate listed entity). It is publicly traded on the BSE and NSE. Recent disclosures put headcount around 17,000 and consolidated revenue at roughly ₹6,672 crore in FY2025 and ₹7,345 crore in FY2026.

The company is a vertically integrated generics manufacturer, organized into three divisions (FY2024 revenue shares in parentheses): international generics formulations (44.7%), domestic branded formulations in India (35.3%), and APIs (20.0%). The US is the largest market within international generics, contributing about 28% of group revenue, with 260+ ANDAs filed and 197 approved as of March 2024. Its Indian branded business markets 100-plus brands, with chronic therapies the largest segment. It operates US FDA-approved formulation and API plants in Vadodara and Hyderabad, plus formulation R&D in the US, and reports 1,200+ R&D staff.

Litigation posture: an operating company, not an assertion entity. The tracked data show a single case, in which Alembic is a defendant, and zero cases as plaintiff — the classic Hatch-Waxman pattern of a generic ANDA filer being sued by a brand manufacturer. Venue is the District of New Jersey, not a plaintiff-friendly Texas venue; Celgene's Revlimid/Thalomid generics suits were generally filed in D.N.J., where the brand company is based and where related multi-district proceedings were venued.

Notable case: Celgene Corp. v. Alembic Pharmaceuticals Ltd. et al. (D.N.J.), brought after Alembic filed an ANDA for lenalidomide, a generic version of Revlimid. Alembic was sued alongside other ANDA filers (Hikma, Aurobindo, Torrent, Biocon, Lupin); co-defendants include Alembic Global Holding SA and US subsidiary Alembic Pharmaceuticals, Inc. Follow-on antitrust complaints (e.g., Cigna Corp. v. Celgene) cite these suits among alleged "sham" litigation — an allegation by those plaintiffs, not a court finding.